Literature DB >> 19893307

Baseline diabetic status and admission blood glucose were poor prognostic factors in the EPITHET trial.

D A De Silva1, M Ebinger, S Christensen, M W Parsons, C Levi, K Butcher, P A Barber, C Bladin, G A Donnan, S M Davis.   

Abstract

BACKGROUND: Previous data have suggested that diabetes and hyperglycemia predict poor outcome following stroke. We studied the prognostic impact of diabetes and admission blood glucose in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET).
METHODS: EPITHET was a prospective randomized placebo-controlled trial of intravenous tissue plasminogen activator (tPA) in the 3- to 6-hour time window. A preexisting diagnosis of diabetes was noted and baseline serum glucose was measured.
RESULTS: Intravenous tPA attenuated infarct growth in non-diabetics, but not in diabetics (p = 0.029). In the tPA treatment group, admission blood glucose was higher among patients with poor functional outcome (p = 0.002).
CONCLUSIONS: Diabetes and hyperglycemia attenuate the effects of tPA on infarct evolution. Future thrombolytic trials should consider randomizing patients by subgroups based on diabetic status and serum glucose levels.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19893307     DOI: 10.1159/000255969

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  20 in total

1.  Proteomic Protease Substrate Profiling of tPA Treatment in Acute Ischemic Stroke Patients: A Step Toward Individualizing Thrombolytic Therapy at the Bedside.

Authors:  Mingming Ning; David A Sarracino; Ferdinando S Buonanno; Bryan Krastins; Sherry Chou; David McMullin; Xiaoying Wang; Mary Lopez; Eng H Lo
Journal:  Transl Stroke Res       Date:  2010-12-01       Impact factor: 6.829

2.  Adverse effects of bone marrow stromal cell treatment of stroke in diabetic rats.

Authors:  Jieli Chen; Xinchun Ye; Tao Yan; Chunling Zhang; Xiao-Ping Yang; Xu Cui; Yishen Cui; Alex Zacharek; Cynthia Roberts; Xinfeng Liu; Xiangguo Dai; Mei Lu; Michael Chopp
Journal:  Stroke       Date:  2011-09-22       Impact factor: 7.914

3.  Hyperglycemia promotes tissue plasminogen activator-induced hemorrhage by Increasing superoxide production.

Authors:  Seok Joon Won; Xian Nan Tang; Sang Won Suh; Midori A Yenari; Raymond A Swanson
Journal:  Ann Neurol       Date:  2011-10-14       Impact factor: 10.422

4.  [Update Stroke Conference 2011: International Stroke Conference 2011, Los Angeles, USA].

Authors:  M Ebinger; M Endres
Journal:  Nervenarzt       Date:  2011-10       Impact factor: 1.214

Review 5.  [Difficult decisions in stroke therapy].

Authors:  M Endres; M Grond; W Hacke; M Ebinger; P D Schellinger; M Dichgans
Journal:  Nervenarzt       Date:  2011-08       Impact factor: 1.214

Review 6.  Considering hyperglycemia and thrombolysis in the Stroke Hyperglycemia Insulin Network Effort (SHINE) trial.

Authors:  Andrew M Southerland; Karen C Johnston
Journal:  Ann N Y Acad Sci       Date:  2012-09       Impact factor: 5.691

7.  Impaired fasting glucose is associated with unfavorable outcome in ischemic stroke patients treated with intravenous alteplase.

Authors:  E Osei; S Fonville; A A M Zandbergen; P J Koudstaal; D W J Dippel; H M den Hertog
Journal:  J Neurol       Date:  2018-04-17       Impact factor: 4.849

8.  Effects of minocycline plus tissue plasminogen activator combination therapy after focal embolic stroke in type 1 diabetic rats.

Authors:  Xiang Fan; Eng H Lo; Xiaoying Wang
Journal:  Stroke       Date:  2013-02-19       Impact factor: 7.914

Review 9.  Pharmaco-proteomics opportunities for individualizing neurovascular treatment.

Authors:  M M Ning; M Lopez; D Sarracino; J Cao; M Karchin; D McMullin; X Wang; F S Buonanno; E H Lo
Journal:  Neurol Res       Date:  2013-06       Impact factor: 2.448

10.  Acute ischemic stroke patients with diabetes should not be excluded from intravenous thrombolysis.

Authors:  Blanca Fuentes; Andrés Cruz-Herranz; Patricia Martínez-Sánchez; Ana Rodríguez-Sanz; Gerardo Ruiz Ares; Daniel Prefasi; Borja E Sanz-Cuesta; Manuel Lara-Lara; Exuperio Díez-Tejedor
Journal:  J Thromb Thrombolysis       Date:  2014-11       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.